Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Zymeworks Inc. (ZYME)

5.55   0.34 (6.53%) 05-16 08:44
Open: 5.31 Pre. Close: 5.21
High: 5.59 Low: 5.195
Volume: 1,147,289 Market Cap: 321(M)
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; BeiGene, Ltd.; and Exelixis, Inc. It also has licensing and research collaboration with LEO Pharma A/S to research, develop, and commercialize bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 5.6 - 5.63 5.63 - 5.65
Low: 5.13 - 5.16 5.16 - 5.19
Close: 5.49 - 5.55 5.55 - 5.6

Technical analysis

as of: 2022-05-16 8:22:55 AM
Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected.
Target: Six months: 7.72     One year: 9.2
Support: Support1: 4.55    Support2: 3.79
Resistance: Resistance1: 6.61    Resistance2: 7.88
Pivot: 5.78
Moving Average: MA(5): 5.41     MA(20): 5.62
MA(100): 8.49     MA(250): 20.72
MACD: MACD(12,26): -0.3     Signal(9): -0.3
Stochastic oscillator: %K(14,3): 26.4     %D(3): 23.9
RSI: RSI(14): 45.5
52-week: High: 39.4  Low: 4.55
Average Vol(K): 3-Month: 1,721 (K)  10-Days: 1,786 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ ZYME ] has closed above bottom band by 42.2%. Bollinger Bands are 4.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Mon, 16 May 2022
Zacks: Brokerages Expect Zymeworks Inc. (NYSE:ZYME) Will Post Quarterly Sales of $7.56 Million - MarketBeat

Wed, 04 May 2022
Zymeworks Inc. (ZYME) CEO Kenneth Galbraith on Q1 2022 Results - Earnings Call Transcript - Seeking Alpha

Mon, 02 May 2022
Zymeworks Announces Participation in Upcoming Investor Conferences - Business Wire

Mon, 02 May 2022
Short Squeeze Stocks: HCDI, ZYME and 3 Others Experts Think Are Ready to Pop - InvestorPlace

Fri, 29 Apr 2022
Pre-Market Most Active for Apr 29, 2022 : FNCH, DIDI, ZYME, TQQQ, SQQQ, AAPL, NIO, BABA, QQQ, PDD, CTVA, BEKE - Nasdaq

Fri, 29 Apr 2022
Hot Stocks: Chinese internet stocks rise; ACCD drops 50%; VRSN sets low; ZYME jumps - Seeking Alpha

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NYSE
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 47 (M)
Shares Float 40 (M)
% Held by Insiders 0.8 (%)
% Held by Institutions 82.1 (%)
Shares Short 6,020 (K)
Shares Short P.Month 3,810 (K)

Stock Financials

EPS -4.45
EPS Est Next Qtl -0.68
EPS Est This Year -2.99
EPS Est Next Year -2.54
Book Value (p.s.) 5.98
Profit Margin (%) 0
Operating Margin (%) -944
Return on Assets (ttm) -26.8
Return on Equity (ttm) -59.3
Qtrly Rev. Growth 66.3
Gross Profit (p.s.) -2.79
Sales Per Share 0.48
EBITDA (p.s.) -4.48
Qtrly Earnings Growth 0
Operating Cash Flow -190 (M)
Levered Free Cash Flow -146 (M)

Stock Valuations

PE Ratio -1.25
PEG Ratio -0.4
Price to Book value 0.92
Price to Sales 11.48
Price to Cash Flow -1.37

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.